Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449754) titled 'Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma' on Feb. 27.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hanmi Pharmaceutical Company Limited
Condition:
Advanced or Metastatic Melanoma
Intervention:
Drug: Belvarafenib
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: February 12, 2026
Target Sample Size: 45
Countries of Recruitment:
South Korea
To know more, visit https://clinicaltria...